FTSE MIB
32.927,53 +262,32 (+0,80%) Dow Jones
38.589,16 -57,94 (-0,15%) Nasdaq
17.688,88 +21,28 (+0,12%) Nikkei 225
38.102,44 -712,12 (-1,83%) Petrolio
78,27 -0,18 (-0,23%) Bitcoin EUR
61.644,28 -283,73 (-0,46%)
Day One Biopharmaceuticals, Inc. (DAWN)
Dopo ore:
| Chiusura precedente | 12,92 |
| Aperto | 12,74 |
| Denaro | 12,59 x 200 |
| Domanda | 12,64 x 100 |
| Min-Max giorno | 12,40 - 12,92 |
| Intervallo di 52 settimane | 9,67 - 18,07 |
| Volume | |
| Media Volume | 1.122.157 |
| Capitalizzazione | 1,102B |
| Beta (mensile su 5 anni) | -1,53 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,50 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 35,63 |
GlobeNewswireDay One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
Overall response rate (ORR) greater than 50% across three assessment criteria Median duration of tovorafenib treatment of 15.8 months as of June 5, 2023, with 66% of patients remaining on treatment FDA filing decision expected by mid-November BRISBANE, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages wit
- GlobeNewswire
Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience
Day One receives an exclusive license to develop and commercialize small molecule drug candidates for pediatric and adult cancers with high unmet need Collaboration augments Day One’s portfolio of targeted therapies in oncology BRISBANE, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced
- GlobeNewswire
Day One Reports Second Quarter 2023 Financial Results and Corporate Progress
Results from FIREFLY-1 demonstrate overall response rate (ORR) of 67% and clinical benefit rate (CBR) of 93% in 69 heavily pretreated Response Assessment Neuro-Oncology High-Grade Glioma (RANO-HGG) evaluable patients presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Initiated rolling submission of the tovorafenib New Drug Application (NDA) in relapsed or progressive pediatric low-grade glioma (pLGG) in May 2023 The Company expects to complete the rolling submissio
